Understanding how immune responses can help treat resistant prostate cancer
Official title: Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer
Funded at University of Nebraska Medical Center · NIH-10897051 · Data updated 2026-11-12
This study is looking at how certain immune cells in the blood of men with advanced prostate cancer respond to the disease, especially in the bones, to understand how their function changes over time and how treatment affects them, with the goal of finding better ways to fight the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $333,575 |
| NIH project number | 5R01CA274605-03 |
| Project ID | NIH-10897051 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include men diagnosed with metastatic castration-resistant prostate cancer, particularly those who have undergone androgen deprivation therapy.
✕Less likely to help
Patients with localized prostate cancer or those who have not received androgen deprivation therapy may not benefit from this research.
What this research studies
This research investigates the immune response of polymorphonuclear leukocytes (PMNs) in patients with metastatic castration-resistant prostate cancer (mCRPC), particularly focusing on how these immune cells interact with the cancer in the bone environment. The study aims to identify the changes in PMN function as the disease progresses and how androgen deprivation therapy (ADT) affects these immune responses. By analyzing blood samples from patients at various stages of prostate cancer, the research seeks to uncover mechanisms of resistance to treatment and develop new therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced prostate cancer who currently have limited effective therapies.
How similar studies have gone: Previous research has shown promising results in understanding immune responses in cancer treatment, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Mathew, Grinu — University of Nebraska Medical Center
- Study coordinator: Mathew, Grinu
Related research
Other NIH-funded projects on the same topics.
-
Combination immunotherapy with radioligand therapy for metastatic prostate cancer
A study aims to help men with advanced prostate cancer by combining immune therapy with targeted radiation to boost the body’s own defense against cancer.
-
Understanding what drives lethal metastatic prostate cancer in men
This grant looks at why some prostate cancers become deadly and spread, using patient-derived cells and mouse models.
-
Off-the-shelf tumor cell vaccine tailored to your tumor’s HLA type for advanced prostate cancer
A new vaccine approach uses donor cancer cells matched to a patient’s immune system to help fight advanced prostate cancer.
-
ASH1L’s role in metastatic prostate cancer and its immune environment
Aims to understand how the ASH1L gene helps prostate cancer spread and how it shapes the immune environment in bone metastases so future therapies can target this process.
-
Molecular drivers of lineage changes and new therapies for metastatic prostate cancer
A multi-year study at a major university will explore how metastatic prostate cancer changes its cell type and how to target those changes to help patients.
-
How gut bacteria may affect prostate cancer therapy and resistance
A new study looks at how gut bacteria make compounds that influence prostate cancer treatments and may drive resistance to therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.